Medical Cannabis in the United States: Comparing 2017 and 2024 State Qualifying Conditions to the 2017 National Academies of Sciences Report
Most QCs lack evidence for use on the basis of the 2017 NAS report. Many states recommend QCs with little evidence (amyotrophic lateral sclerosis) or even those for which MC is ineffective (depression). These findings highlight a disparity between state-level MC recommendations and the evidence to support them.
Authors
- Kevin F. Boehnke (ORCID: https://orcid.org/0000-0003-3696-3979)
- Brian J. Piper (ORCID: https://orcid.org/0000-0002-2295-445X)
- Amy L. Kennalley (ORCID: https://orcid.org/0000-0003-1845-7765)
- Maria Tian
- Elena Lynn Stains (ORCID: https://orcid.org/0000-0002-5827-0412)
- Chadd K. Kraus
Institutions
- Geisinger Medical Center (US)
- Lehigh Valley Hospital-Pocono (US)
- University of Michigan (US)
- Michigan Medicine (US)
- Michigan Center for Translational Pathology (US)
- Michigan Psychoanalytic Institute (US)
- Geisinger Health System (US)
- Geisinger Commonwealth School of Medicine (US)
Publication Details
- Journal
- Mayo Clinic Proceedings Innovations Quality & Outcomes
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1016/j.mayocpiqo.2025.100590
- Citations
- 4
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- Geisinger Commonwealth School of Medicine